Hopp til innhold
NHI.no
Annonse

Magesekkreft: Forekomst

Innhold i artikkelen

Hvert år får omlag 400 mennesker i Norge kreft i magesekken. Sykdommen forekommer hyppigst hos middelaldrende og eldre mennesker (65 til 75 år). Lidelsen kan i sjeldne tilfeller forekomme hos personer helt ned i 20 til 30-årsalder. Sykdommen opptrer hyppigere hos menn enn hos kvinner (235 menn, 157 kvinner i 2018). Kreft i magesekken kan være en alvorlig sykdom, men jo tidligere den blir oppdaget, desto bedre er muligheten for helbredelse. I Norge og hele den vestlige verden forøvrig, har det i mange år vært en nedgang i antall tilfeller av sykdommen, noe som gjelder alle aldersgrupper. Magekreft forekommer hyppigst i Japan og Kina. I Europa er det noe lavere forekomst, men lavest forekomst finnes i Nord-Amerika og Afrika.

Animasjon av kreft i magesekken

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Ventrikkelkreft . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i magesekken (ventrikkelkreft). 15.06.2018. helsedirektoratet.no
  2. Murphy MB, Reed V. Stomach cancer. BestPractice, last updated Jan 2016.
  3. Kreftregisteret. Cancer in Norway 2018. Oslo: Kreftregisteret, 2019. www.kreftregisteret.no. www.kreftregisteret.no
  4. Walther C, Silling T, Perfekt R, Möller T. Adenocancer i esofagus och ventrikelns kardiaregion öker kraftigt. Läkartidningen 2004; 101: 180-3. pmid: 11775726 PubMed
  5. Layke JC, Lopez PP. Gastric cancer: Diagnosis and treatment options. Am Fam Physician 2004; 69: 1133-40. PubMed
  6. Watari J, Chen N, Amenta PS, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol. 2014;20(18):5461-5473. doi:10.3748/wjg.v20.i18.5461 DOI
  7. Kamangar F, Dawsey SM, Blaser MJ et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with helicobacter pylori seropositivity. J Natl Cancer Inst 2006; 98: 1445-52. PubMed
  8. Fukase K, Kato M, Kikuchi S et al. and for the Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7. PubMed
  9. Kuipers EJ. Review article: Exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 1999; 13 (suppl 1): 3-11. pmid: 10209681 PubMed
  10. Schaffalitzky de Muckadell OB. Ulcus pepticum og cancer ventriculi - infektionssygdomme fremkaldt af Helicobacter pylori?. Ugeskr Læger 2002; 164, nr. 50. pmid: 12553117 PubMed
  11. Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage respons in its host cells. Proc Natl Acad Sci 2011; 108: 14944-9. PubMed
  12. Fock KM, Talley NJ, Moayyedi P et al. Asia Pacific Consensus Guideline on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-65. PubMed
  13. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. A randomized controlled trial. JAMA 2004; 291;187-94. pmid: 14722144 PubMed
  14. Lee Y-C, Chiang T-H, Chou C-K, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: a Systematic Review and Meta-analysis. Gastroenterology. 2016 Jan 30 . pmid: 26836587 PubMed
  15. Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am 2002; 31: 517-35. PubMed
  16. Bartley AN, Washington MK, Colasacco C et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017; 35(4): 446-64. pmid:28129524 PubMed
  17. Stapley S, Peters TJ, Neal RD et al. The risk of oesophago-gastric cancer in symptomatic patients in primary care: a large case-control study using electronic records. Br J Cancer. 2013;108:25-31. PMID: 23257895. PubMed
  18. Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH. Gastric cancer. Lancet 2009;374:477-90. PubMed
  19. Wan QY, Wu XT, Li N, Du L, Zhou Y. Long-term proton pump inhibitors use and risk of gastric cancer: a meta-analysis of 926 386 participants. Gut. 2019;68(4):762-764. doi:10.1136/gutjnl-2018-316416 DOI
  20. Jiang K, Jiang X, Wen Y, Liao L, Liu FB. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol. 2019;34(11):1898-1905. doi:10.1111/jgh.14759 DOI
  21. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224(3):748-56. PubMed
  22. Talley NJ. Is it time to screen and treat H pylori to prevent gastric cancer?. Lancet 2008; 372: 350-2. PubMed
  23. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. pmid: 16822992 PubMed
  24. Ohtani H, Tamamori Y, Noguchi K, et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg 2010;14:958-964. PubMed
  25. Mamon H, Enzinger PC. Adjuvant and neoadjuvant treatment of gastric cancer. UpToDate, last updated Jan 18, 2019. UpToDate
  26. Keishiro Aoyagi, Kikuo Kouhuji, Junya Kizaki et al. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20: 13741-55. pmid:25320512 PubMed
  27. Ohtsu A1, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-76. pmid:21844504 PubMed
  28. Heiss MM1, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-21. pmid:20473913 PubMed
  29. Mabe K, Takahashi M, Oizumi H, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?. World J Gastroenterol 2009; 15: 4290-7. PubMed
  30. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10(10):1055-62. PubMed
  31. Rønning, G. Kreft i magesekk. Oncolex. Sist revidert juni 2014. oncolex.no
Annonse
Annonse